Last updated: April 30, 2026
What is EP3363810 and what protection does it seek in Europe?
EP3363810 is an EP-family patent application/patent published by the European Patent Office (EPO) that is assigned a drug-protecting function typical of pharmaceutical inventions: it claims compositions and/or therapeutic methods involving a specific active ingredient or a defined use-context. The EPO record and claim set determine the legal scope, including claim construction, dependent claim fall-through, and the technical features that limit infringement.
However, a complete, accurate scope-and-claims landscape cannot be produced from the information in this prompt. The underlying file history, claim text, and family members are required to map:
- exact claim wording and dependency structure;
- whether claims cover substance, composition, formulation, dosing regimen, or method-of-treatment;
- priority chain and likely therapeutic field;
- validation status per EPC contracting states;
- oppositions, limitation/amendment outcomes, and claim narrowing.
Because the prompt does not provide the claim text, IPC/CPC, assignee, title, priority date, publication number equivalents (WO/US), or EPO legal status, any attempt to describe scope, claim elements, or landscape would risk being wrong.
What do the claims cover (substance, composition, method) and how broad is the protection?
A claim-by-claim scope requires the actual EPO claim set, including:
- independent claims (the anchor for infringement and validity);
- dependent claims (their narrowing features);
- whether the claims use Markush-style alternatives, parameter ranges, or functional language;
- whether the claims are limited to specified formulations or patient subgroups;
- whether the claims cover “use” categories under EPC 2000 (Article 53(c)).
Without the EPO claim text, it is not possible to determine:
- which technical features are essential;
- the permitted ranges and how many are actually claimed;
- whether the protection includes combinations or only monotherapy;
- whether the invention is positioned around a specific polymorph, salt, hydrate, solvent, particle size, or device.
How does EP3363810 sit within the European patent landscape (same drug, same MoA, same class)?
A defensible landscape analysis in Europe requires:
- the drug identity (active ingredient and target);
- the priority date and expiry drivers (including supplementary protection certificates, if applicable);
- nearby patents: formulation, salt/polymorph, dosing, combination therapy, and manufacturing process;
- procedural status: oppositions filed at EPO, opposition outcomes, and whether claims remain as granted or were limited;
- family synchronization: whether there are parallel grants in EP member states and their post-grant event history.
Without the identity of the claimed drug and the EPO legal file data, the landscape cannot be mapped to specific competitors, filing patterns, or enforcement risk.
What is the procedural and legal status impact on claim scope in Europe?
For EPO patents, scope often changes through:
- opposition proceedings (Article 99 EPC);
- limitation or amendment during prosecution;
- appeal outcomes affecting the effective claim set.
The effective enforceable claim set depends on the grant and any subsequent EPO decisions. The prompt provides no status information, so the current enforceable scope cannot be stated.
What are the key risk points for enforcement or freedom-to-operate (FTO) around EP3363810?
An enforcement/FTO view depends on:
- whether the independent claims are narrow (specific formulations/doses) or broad (broad Markush or functional claims);
- whether the claim set survived novelty/inventive step scrutiny;
- whether there are earlier priority filings that render the claims invalid or narrow them via interpretation;
- whether the drug is protected by SPCs, which can extend exclusivity and change FTO timing.
None of those determinants are available in the prompt.
How to interpret EP-style claim language for infringement in Europe (claim construction framework)
Even without the claim text, the EPO and infringement practice typically turns on:
- literal wording of the essential technical features;
- equivalents only where local infringement rules allow it;
- dependent claims: a feature added by dependency becomes part of the claim scope and the accused product must contain it;
- parameters/ranges: infringement can hinge on whether an accused formulation falls within the claimed numerical boundaries;
- functional language: if claims are limited by achievable performance definitions, construction will track how the description supports the functional definition.
This is not a substitute for the missing, required EP3363810 claim text.
Key Takeaways
- A precise analysis of scope and claims for EP3363810 requires the actual EPO claim set, description-supported claim construction anchors, and procedural status.
- A credible European patent landscape mapping requires the drug identity (active ingredient/target), the priority chain, family members, and EPO legal status.
- The prompt does not include the file-specific data needed to produce a complete and accurate EP3363810 analysis.
FAQs
-
What inputs are required to analyze EP3363810 claim scope accurately in Europe?
The EPO claim text (independent and dependent), bibliographic data (title, assignee, priority), and current legal status (granted as filed vs amended/limited).
-
Can a landscape analysis be done without knowing the drug and priority dates?
No. Landscape mapping depends on drug identity, therapeutic area, and priority chronology to identify overlapping protection.
-
How do opposition outcomes typically affect EPO claim scope?
They can narrow or rewrite claims through amendment and can remove claim categories, changing infringement and validity risk.
-
Are EPO drug patents assessed under EPC Article 53(c) for methods and uses?
Yes, the EPC claim category and compliance with exclusions for methods of treatment matter, but you must see the exact claim language used by EP3363810.
-
Does EP3363810 likely interact with SPC protection in Europe?
Often drug patents do, but the presence and term of an SPC depend on the market authorization and the specific claim category protecting the medicinal product, which cannot be determined from the prompt.
References (APA)
[1] European Patent Office. EP3363810. EPO Register and publication data.
